Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 26 (9), 354-362

Beyond Cystic Fibrosis Transmembrane Conductance Regulator Therapy: A Perspective on Gene Therapy and Small Molecule Treatment for Cystic Fibrosis

Affiliations
Review

Beyond Cystic Fibrosis Transmembrane Conductance Regulator Therapy: A Perspective on Gene Therapy and Small Molecule Treatment for Cystic Fibrosis

Elena K Schneider-Futschik. Gene Ther.

Abstract

Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent advent of the FDA-approved CFTR modulator drug ivacaftor, alone or in combination with lumacaftor or tezacaftor, has enabled treatment of the majority of patients suffering from CF. Even before the identification of the CFTR gene, gene therapy was put forward as a viable treatment option for this genetic condition. However, initial enthusiasm has been hampered as CFTR gene delivery to the lungs has proven to be more challenging than expected. This review covers the contemporary clinical and scientific knowledge base for small molecule CFTR modulator drug therapy, gene delivery vectors and CRISPR/Cas9 gene editing and highlights the prospect of these technologies for future treatment options.

Similar articles

See all similar articles

MeSH terms

Feedback